Clinical Trial Update: Clazakizumab for the Treatment of Chronic Active Antibody Mediated Rejection in Kidney Transplant Recipients [Phase 3]

View source ↗

Summary

A Phase 3 trial of clazakizumab for chronic active antibody-mediated rejection in kidney transplant recipients was terminated, with results posted in July 2025.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Antibody-mediated Rejection

Drugs mentioned

• Clazakizumab (clazakizumab)

Snippet

Sponsor: CSL Behring | Conditions: Antibody-mediated Rejection | Phase 3 | Status: TERMINATED | Results posted: 2025-07-23